ORNBV Orion Oyj Class B

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market

ORION CORPORATION

PRESS RELEASE

23 MAY 2025 at 12.40 EEST

        

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market

Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited (“Shilpa”), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa’s Recombinant Human Albumin is developed using a robust non-human expression system ensuring high safety, scalability, and virus-free production, addressing key limitations associated with human-derived albumin. The product is currently under development by Shilpa.

Under the terms of the agreement, Orion will gain exclusive right to distribute, market and sell Shilpa’s Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments.

“We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,” said Satu Ahomäki, EVP Generics and Consumer Health, Orion Corporation. “Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.”

“Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental and manufacturing capabilities to bring Recombinant Human Albumin to market,” said Madhav Bhutada, Managing Director, Shilpa Biocare. “This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets.”

Orion Corporation

Contact person:

Satu Ahomäki, EVP, Generics and Consumer Health, Orion Corporation

tel. +358 10 426 7616

                                                 

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.



EN
23/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion publishes Half-Year Financial Report for January–June 2025 and h...

Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025 ORION CORPORATION PRESS RELEASE 4 JULY 2025 at 09.00 EEST                    Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025 Orion will publish Half-Year Financial Report for January–June 2025 on Friday, 18 July 2025 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company’s website at after publishing. Webcast and conference call A webcast and a conference call for analysts, in...

 PRESS RELEASE

Orion julkaisee puolivuosikatsauksen 1–6/2025 ja järjestää verkkolähet...

Orion julkaisee puolivuosikatsauksen 1–6/2025 ja järjestää verkkolähetyksen 18.7.2025 ORION OYJ                LEHDISTÖTIEDOTE 4.7.2025 KLO 9.00          Orion julkaisee puolivuosikatsauksen 1–6/2025 ja järjestää verkkolähetyksen 18.7.2025 Orion julkaisee puolivuosikatsauksen 1–6/2025 perjantaina 18.7.2025 noin klo 12.00. Katsaus ja siihen liittyvä esitysmateriaali ovat julkistuksen jälkeen saatavilla yhtiön verkkosivuilla osoitteessa . Verkkolähetys ja puhelinkonferenssi Englanninkielinen verkkolähetys sekä puhelinkonferenssi analyytikoille, sijoittajille ja toimittajille järjestetään ...

 PRESS RELEASE

141,959 Orion Corporation A shares converted into B shares

141,959 Orion Corporation A shares converted into B shares ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 23 June 2025 at 9.30 EEST         141,959 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 141,959 A shares have been converted into 141,959 B shares. The conversion has been entered into the Trade Register on 23 June 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,308,783 ...

 PRESS RELEASE

141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi ORION OYJ        PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT         23.6.2025 KLO 9.30          141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 141 959 A-osaketta 141 959 B-osakkeeksi. Muuntaminen on merkitty kaupparekisteriin 23.6.2025. Orion Oyj:n osakkeiden kokonaismäärä on 141 134 278 kpl. Muuntamisen jälkeen A-osakkeita on 32 308 783 kpl ja B-osakkeita 108 825 495 kpl. Yhtiön osakkeiden tuottama äänimäärä muunnon jälkeen on yhteensä...

 PRESS RELEASE

CHMP recommends third indication for darolutamide for patients with ad...

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST           CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union.Positive opinion is based on results from the pivotal Phase III ARANOTE trial.Pending approval, this broadened in...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch